Michail Vikelis

8 Ilias Str
Glyfada, ESYE31, Greece

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 63 publications

Re-assessing the clinical significance of long-term neuromuscular alterations following Onabotulinumtoxin-A (BoNTA) in chronic migraine: Letter to the editor on behalf of the GRASP study group.

Re-assessing the clinical significance of long-term neuromuscular alterations following Onabotulinumtoxin-A (BoNTA) in chronic migraine: Letter to the editor on behalf of the GRASP study group.

Journal: Clinical neurophysiology practice

Published: July 21, 2026

Effectiveness and safety of sumatriptan 85 mg/naproxen sodium 500 mg combination for acute migraine: prospective real-world evidence from the GRASP Study Group.

Effectiveness and safety of sumatriptan 85 mg/naproxen sodium 500 mg combination for acute migraine: prospective real-world evidence from the GRASP Study Group.

Journal: Frontiers in neurology

Published: June 17, 2026

Achieving International Headache Society-aspired optimal migraine control in fremanezumab-treated patients: A post-hoc analysis of a real-world, prospective study from the GRASP study group.

Achieving International Headache Society-aspired optimal migraine control in fremanezumab-treated patients: A post-hoc analysis of a real-world, prospective study from the GRASP study group.

Journal: Cephalalgia : an international journal of headache

Published: June 04, 2026

Botulinumtoxin Type-A (BoNTA) in the Management of Refractory Trigeminal Neuralgia: An Expert-Opinion, Practice-Oriented Narrative Review on Behalf of the GRASP Study Group.

Botulinumtoxin Type-A (BoNTA) in the Management of Refractory Trigeminal Neuralgia: An Expert-Opinion, Practice-Oriented Narrative Review on Behalf of the GRASP Study Group.

Journal: Toxins

Published: May 11, 2026

Comparing the Efficacy and Safety of Anti-CGRP Monoclonal Antibodies Versus Topiramate for Migraine Prophylaxis: Six-Month, Real-World, Intention-to-Treat Retrospective Evidence from the GRASP Study Group.

Comparing the Efficacy and Safety of Anti-CGRP Monoclonal Antibodies Versus Topiramate for Migraine Prophylaxis: Six-Month, Real-World, Intention-to-Treat Retrospective Evidence from the GRASP Study Group.

Journal: Neurology international

Published: March 05, 2026

Association between TNFa rs1800629 and migraine: Case-control study and updated meta-analysis.

Association between TNFa rs1800629 and migraine: Case-control study and updated meta-analysis.

Journal: AIMS neuroscience

Published: December 12, 2025

Eptinezumab to prevent difficult-to-treat migraine: prospective, six-month, real-world multicenter evidence from the GRASP study group.

Eptinezumab to prevent difficult-to-treat migraine: prospective, six-month, real-world multicenter evidence from the GRASP study group.

Journal: The journal of headache and pain

Published: November 29, 2025

Testing the Efficacy of Eptinezumab 100 mg in the Early Prevention of Chronic Migraine over Weeks 1 to 4: Prospective Real-World Data from the GRASP Study Group.

Testing the Efficacy of Eptinezumab 100 mg in the Early Prevention of Chronic Migraine over Weeks 1 to 4: Prospective Real-World Data from the GRASP Study Group.

Journal: Journal of clinical medicine

Published: November 24, 2025

Efficacy of single-dose galcanezumab 240 mg on episodic or refractory chronic cluster headache: prospective, 4-week, real-world evidence from the GRASP study group.

Efficacy of single-dose galcanezumab 240 mg on episodic or refractory chronic cluster headache: prospective, 4-week, real-world evidence from the GRASP study group.

Journal: Frontiers in neurology

Published: November 17, 2025

OnabotulinumtoxinA to Prevent Chronic Migraine with Comorbid Bruxism: Real-World Data from the GRASP Study Group.

OnabotulinumtoxinA to Prevent Chronic Migraine with Comorbid Bruxism: Real-World Data from the GRASP Study Group.

Journal: Toxins

Published: October 12, 2025

Effects of Pausing and Re-Initiating Fremanezumab After Continuous 24-Month Treatment for Preventing Difficult-To-Treat Migraine: Prospective, Multicenter, Real-World Data From the GRASP Study Group.

Effects of Pausing and Re-Initiating Fremanezumab After Continuous 24-Month Treatment for Preventing Difficult-To-Treat Migraine: Prospective, Multicenter, Real-World Data From the GRASP Study Group.

Journal: European journal of neurology

Published: May 20, 2025

Corrigendum: Unmet needs in the management of migraine in Greece from the perspective of medical experts: a Delphi consensus.

Corrigendum: Unmet needs in the management of migraine in Greece from the perspective of medical experts: a Delphi consensus.

Journal: Frontiers in neurology

Published: March 18, 2025

Showing 1-12 of 63

Last Updated: 09/26/2026